CADTH | Evidence Driven
CADTH | Evidence Driven

alectinib

Details

Generic Name:
alectinib
Project Status:
Received
Therapeutic Area:
ALK-positive NSCLC
Manufacturer:
Hoffmann-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Alecensaro
Project Line:
Reimbursement Review
Project Number:
PC0350-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Alecensaro as adjuvant treatment following tumour resection in adult patients with Stage IB (4 cm) - IIIA (according to AJCC/UICC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Pending
Indications:
Alecensaro ​as adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openMarch 06, 2024
Call for patient/clinician input closedApril 30, 2024
Submission receivedApril 18, 2024
Submission accepted-
Last Updated : April 19, 2024